Amyris, Inc. (NASDAQ:AMRS)

Many analysts are providing their Estimated Earnings analysis for Amyris, Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.08/share. Amyris Inc has a one year low of $0.31 and a one year high of $1.44. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels.

The 52-week high of the share price is -67.88% and 52-week low of the share price is 49.19%.

A number of research analysts recently commented on AMRS shares. Rodman & Renshaw restated a "buy" rating and set a $4.00 price target on shares of Amyris in a report on Wednesday, January 11th. Analysts have a mean recommendation of 2.00 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock.

When we look at the recommendation trends, the stock presently has an average brokerage recommendation of 0.6.

Amyris, Inc. (NASDAQ:AMRS) shares typically trade an average volume of 2330.80 and institutions hold 33.90% of the total shares. 5,374,144 shares of the stock were exchanged.

The firm's market capitalization is $124.17 million. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of -10.11%. The stock has its 52-Week High on Mar 1, 2017 and 52-Week Low on Jul 6, 2016.

Amyris (NASDAQ:AMRS) last released its earnings results on Thursday, March 2nd. (NASDAQ:AMRS) reported its EPS in the last quarter as $-0.14/Share lagging the analyst estimate of $-0.06/Share by the difference of $-0.08. According to their predictions High & Low revenue estimates are 41.06 Million and 23.5 Million respectively. The business's revenue for the quarter was up 228.6% compared to the same quarter past year. During the same quarter in the prior year, the company earned ($0.16) EPS. Equities analysts expect that Amyris Inc will post ($0.25) earnings per share for the current fiscal year.

This news story was reported by BBNS and is the sole property of of BBNS. If you are reading this story on another site, it was copied illegally and reposted in violation of United States & global copyright & trademark law. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/amyris-inc-amrs-downgraded-by-zacks-investment-research/488788.html. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/03/07/amyris-inc-amrs-major-shareholder-mauritius-pte-ltd-maxwell-sells-868589-shares-of-stock.html. The shares were sold at an average price of $0.52, for a total value of $149,607.12. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms.

An institutional investor recently raised its position in Amyris stock. Amyris, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0. The company's outstanding shares are 1.33 Billion.

  • Zachary Reyes